Previous Article | Next Article ![]()
Journal of Virology, October 2000, p. 9019-9027, Vol. 74, No. 19
The Marjorie B. Kovler Viral Oncology
Laboratories, The University of Chicago, Chicago, Illinois 60637
Received 24 March 2000/Accepted 5 July 2000
Open reading frame (ORF) O and ORF P partially overlap and are
located antisense to the Herpes simplex virus 1 (HSV-1) and
HSV-2 cause two types of infections in humans and experimental animals,
productive and latent. Productive infection at the portal of entry
involves the coordinated expression of >80 open reading frames (ORFs),
replication, assembly of infectious progeny, and destruction of the
cell (reviewed in references 49 and 50)
(20, 21). More than half of the genes are dispensable for
growth in cell culture and appear to have auxiliary functions that
optimize viral replication and spread within its host. From the portal
of entry, HSV infects innervating sensory neurons and is transported
retrograde to the nucleus. The precise sequence of events that follows
is unclear; it seems that in some neurons the virus replicates and
destroys the neurons whereas in others the virus establishes a latent infection.
It is convenient to differentiate three stages of infection of neurons:
the establishment phase, the maintenance phase, and the reactivation
phase. Little is known of the establishment phase since the neurons
which replicate the virus during the first several days after infection
obscure the events taking place in the neurons committed to maintaining
the virus in a latent state. In the maintenance state, signaled by the
disappearance of all traces of replicating virus, viral DNA is
maintained in an episomal form and only a small region of the genome is
transcribed, the latency-associated transcripts (LATs) (55).
The last phase, reactivation, is induced spontaneously in some
experimental animal systems (reviewed in reference
15). It can be induced artificially by explanation and cocultivation of sensory ganglia harboring latent virus. In essence, our knowledge of the requirement for the establishment of
latency has been based on whether latent virus can be detected during
the maintenance stage or as a consequence of induced reactivation. Over
the past decade several genes have been "identified" as playing a
role in the establishment of latency (23, 32, 37, 38, 53, 56,
59). The list includes a large number of ORFs and also the LATs.
In most instances where thorough investigations have been carried out,
it has become apparent that these genes play a key role in viral
replication. Consequently, recombinant viruses mutated in or lacking
these genes replicate poorly at the portal of entry and during
reactivation from latent phase.
The major focus of investigations into genes controlling the
establishment or maintenance of latency has been the LATs, a family of
transcripts arising from the inverted repeats flanking the unique long
(UL) sequence. The full-length 8.3-kb transcript accumulates at low levels in latently infected neurons, while 2.0- and
1.5-kb introns processed from the full-length transcript are abundant
(10, 25, 36, 47, 52, 55, 57, 58, 63). These introns are
highly stable and appear to be lariat structures (14, 48, 60,
62). Viruses with LATs deleted have been reported to establish
latency at levels within a threefold range of the wild type (3,
56). Deletion of LATs reduces the capacity of the virus to cause
productive infections in the mouse and reduces the capacity of the
virus to replicate following explanation of the neurons (2, 18,
22, 31, 50, 51, 54). The region of LAT associated with decreased
reactivation has been mapped to a 348-bp sequence in the 5' end
(3, 19). LAT has not been shown to express ORFs. A recent
report indicated that sequences containing the LAT introns can protect
neurons from apoptosis and that a virus with LAT deleted induces
apoptosis in rabbit trigeminal ganglia at higher levels than the
wild-type virus (39). Thus, at least one function of LAT may
be to promote neuronal survival during the maintenance of latent
infection. Other studies have suggested that viral functions that
repress lytic gene expression in vivo reside within the LAT domain
(6, 16). The effectors of these functions are not
identified. Irrespective of the final determination of the functions of
LATs, the necessary conclusion is that LATs play a role in the
maintenance of the latent state rather than in its establishment.
In earlier studies, we reported that the domain of the inverted repeats
represented in LATs contains 16 ORFs of greater than 50 codons and that
at least two of these, ORF O and ORF P, are expressed (27,
43). ORF O and ORF P are located in the 3' domain of the LAT
domain, almost entirely antisense to the Investigations into the functions of ORF O and ORF P have revealed the
following. (i) ORF P transcription is sufficient to preclude expression
of the antisense It has been predicted that genes that are involved in the establishment
of latency (i) are located within the domain transcribed during
latency, (ii) encode functions which inhibit the lytic gene expression
program, and (iii) are repressed during productive expression, as they
encode genes detrimental to viral replication. ORF O and ORF P fulfill
these criteria and as such are excellent candidates for genes which
regulate the establishment of latency (5, 27-29, 42, 43).
Multiple studies have implicated the ORF O/ORF P/ The goal of this study was to address the significance of ORF O and ORF
P in the virus life cycle without interfering with the expression of
the antisense Cells and viruses.
Rabbit skin and 143tk
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Herpes Simplex Virus 1 Open Reading Frames O
and P Are Not Necessary for Establishment of Latent Infection
in Mice
and
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
134.5 gene within the domain
transcribed during latency. In wild-type virus-infected cells, ORF O
and ORF P are completely repressed during productive infection by ICP4, the major viral transcriptional activator/repressor. In cells infected
with a mutant in which ORF P was derepressed there was a significant
delay in the appearance of the viral
-regulatory proteins ICP0 and
ICP22. The ORF O protein binds to and inhibits ICP4 binding to its
cognate DNA site in vitro. These characteristics suggested a role for
ORF O and ORF P in the establishment of latency. To test this
hypothesis, two recombinant viruses were constructed. In the first,
R7538(P
/O
), the ORF P initiator methionine codon, which also serves
as the initiator methionine codon for ORF O, was replaced and a
diagnostic restriction endonuclease was introduced upstream. In the
second, R7543(P
/O
)R, the mutations were repaired to restore the
wild-type virus sequences. We report the following. (i) The
R7538(P
/O
) mutant failed to express ORF O and ORF P proteins but
expressed a wild-type
134.5 protein. (ii) R7538(P
/O
) yields were similar to that of the wild type following infection of
cell culture or following infection of mice by intracerebral or ocular
routes. (iii) R7538(P
/O
) virus reactivated from latency following
explanation and cocultivation of murine trigeminal ganglia with Vero
cells at a frequency similar to that of the wild type, herpes simplex
virus 1(F). (iv) The amount of latent R7538(P
/O
) virus as assayed
by quantitative PCR is eightfold less than that of the repair virus.
The repaired virus could not be differentiated from the wild-type
parent in any of the assays done in this study. We conclude that ORF O
and ORF P are not essential for the establishment of latency in mice
but may play a role in determining the quantity of latent virus
maintained in sensory neurons.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
134.5 gene.
They are expressed from a promoter and associated RNA internal to and
3' coterminal with LAT (4, 61). This transcript is completely repressed during productive infection by the binding of
ICP4, the major viral transactivator/repressor, to a consensus ICP4
binding site that straddles the ORF P transcriptional initiation site
(13, 26, 28, 29, 33-35, 42, 45, 46, 61). ORF O and ORF P
are expressed only under conditions in which ICP4 repression is
nonfunctional, i.e., in a virus containing a mutated ICP4 binding site
or during infection and maintenance at 39.5°C, the nonpermissive
temperature for ICP4, in HSV-1(F) and other limited-passage clinical
isolates (11, 12). The repression of ORF O by the ICP4
binding site was surprising since ORF O was predicted to begin upstream
of the ORF P transcript. Analyses of the products encoded by the ORFs
showed that the translation of ORF O begins at the ORF P initiator
methionine codon and then shifts into the ORF O reading frame before
the amino acid 35 codon of ORF P (43). Thus, ORF O and ORF P
are expressed under identical conditions and have not been detected
during productive infection.
134.5 gene and attenuates virulence
(29, 42). (ii) ORF P protein inhibits the expression of ICP0
and ICP22. This correlates with an interference in the splicing of
mRNAs inasmuch as (a) ORF P interacts and colocalizes with splicing
factors (5); (b) a virus with ORF O and ORF P expression
derepressed accumulates significantly less ICP0 and ICP22, which are
translated from spliced mRNAs, while the levels of two proteins
synthesized from intronless mRNAs, ICP4 and ICP27, are unchanged
(5, 42); (c) ORF P protein expression is required for the
inhibition of ICP0 and ICP22 expression (42); and (d) ORF P
derepression alters the accumulation of the spliced LAT (30). (iii) ORF O protein specifically binds to and inhibits in vitro binding of ICP4 to its cognate site (43). ICP0 is a promiscuous transactivator required for efficient expression of viral
genes. ICP4, the major viral transcriptional regulator, is required for
the expression of
and
genes. ICP22 positively regulates the
expression of a subset of
and
genes (reviewed in reference
50). Accordingly, ORF O and ORF P interfere with the
expression of multiple
-regulatory genes which promote lytic gene expression.
134.5
domain as important in the latent life cycle. Deletions in this region
result in decreased establishment of and reactivation from latency
(37, 38, 53, 59). However, since
134.5 is
required for virulence, these deletions also result in reduced viral
replication (7-9, 17, 59). Fewer viruses reach the
trigeminal neurons from peripheral sites, and the amount of latent
virus is consequently reduced. A recombinant virus expressing a
truncated ORF P protein and an ORF O protein containing a one amino
acid substitution was reported to reactivate from latency with
frequencies similar to that of the wild type (30). The amount of established latent virus was not examined. The contribution of ORF O and ORF P to the establishment of latency remains unknown.
134.5 gene. ORF P encodes only two
methionines, the initiator and one located eight amino acids from the C
terminus. Previous studies have shown that mutation of the initiator
methionine in the context of the ORF P-derepressed virus is sufficient
to prevent ORF P protein translation (42). We have
previously shown that ORF O may begin at the ORF P initiator methionine
codon, such that mutation of this codon would also prevent ORF O
translation (43). Two recombinant viruses were constructed, (i) R7538(P
/O
), which contains the initiator
methionine codon mutation, and (ii) R7543(P
/O
)R, in which the
mutation was repaired to wild type. R7538(P
/O
) does not express ORF
O and ORF P proteins but does express
134.5 at wild-type
levels. We report that mutants lacking the capacity to synthesize ORF O
and ORF P proteins were not affected in their ability to replicate in
cell culture, mouse central nervous system, mouse eye, or mouse trigeminal ganglia. In the mouse, they established latency but at a
reduced copy number per cell.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
cells
were originally obtained from J. McClaren and Carlo Croce,
respectively. Vero cells were from the American Type Culture
Collection. HSV-1(F) is the prototype HSV-1 strain used in this
laboratory; as is the case with fresh HSV-1 isolates with limited
history of replication outside the human host, the
4 gene of
HSV-1(F) is temperature sensitive and does not repress itself or ORF P
at 39.5°C (12, 27). The recombinant virus R3659 has been
previously described (28). It lacks the SacI-BglII sequence of the BamHI Q
fragment encoding the thymidine kinase (TK) and UL24 genes.
A sequence consisting of the coding domain of the TK gene under the
control of the
27 promoter (40) replaced the
BstEII-StuI sequence of the BamHI S
fragment containing the
134.5 and ORF P genes (Fig.
1, line 4).

View larger version (26K):
[in a new window]
FIG. 1.
Schematic representations of sequence arrangements in
the recombinant viruses used in these studies. (Line 1) Representation
of the HSV-1(F) genome. Shown are the UL and unique short
(US) sequences, which are flanked by inverted repeats c, a,
and b and b', a', and c'. (Line 2) Domains of the ORF O, ORF P, and
134.5 genes in the inverted repeat sequence b' a'
flanking the UL sequences. The coding domains (boxes) and
transcripts (lines with arrows denoting transcription direction) of the
ORF O, ORF P, and
134.5 genes are shown. Solid circle,
wild-type ICP4 binding site. (Line 4) Sequence arrangement of the
relevant domains of R3659. The StuI-BstEII
sequences containing ORF P and
134.5 were replaced in
both repeats by the chimeric
27-tk gene. (Line 6)
Sequence arrangement of the relevant domains of recombinant
R7538(P
/O
). The
27-tk gene of R3659 was replaced with
sequences containing a mutated ORF P initiation methionine codon
introducing a diagnostic AvrII endonuclease site. (Line 8)
Sequence arrangement of the relevant region of recombinant
R7543(P
/O
)R. The mutations in the ORF O/P domain of R7538(P
/O
)
were repaired by transfection with the NcoI fragment from
the HSV-1(F) BamHI S fragment. (Lines 3, 5, 7, and 9)
Expected sizes of fragments detected by hybridization of the 1,800-bp
NcoI fragment with electrophoretically separated digests of
viral DNAs with NcoI-AvrII, diagnostic of the
replacement of the initiator methionine. Arrows, restriction cleavage
sites present in the respective viruses and therefore fragment
boundaries. HSV-1(F) DNA would be expected to yield band A, R3659 DNA
would be expected to yield band B, R7538(P
/O
) DNA would be expected
to yield bands C and D, and R7543(P
/O
)R DNA would be expected to
yield band E. Abbreviations: St, StuI; Nc, NcoI;
Bs, BstEII.
Antibodies.
Rabbit polyclonal antisera specific for
134.5, BR4 (1), and rabbit polyclonal
antisera specific for ORF O (43) have been described previously.
Plasmids.
pRB4930 contains the 830-bp NotI
fragment of BamHI S cloned into the NotI site of
pUC19. Plasmid pBR4929 contains a mutant ORF P initiator methionine
codon and was made by insertion of a 160-bp PCR product into the
SrfI-DraIII sites of pRB4930. The PCR primers
were
5'-ACGGGCCTCGGGCCCTAGGCACGGCCCGATAACCGCCTCGGCCTC and 5'-GAGGCCGAGGCGGTTATCGGGCCGTGCCTAGGGCCCGAGGCCCGT.
Underlined bases represent mutations that replace the ORF P
initiator methionine codon (ATG) with an isoleucine codon (ATA) and
create a diagnostic AvrII restriction site 15 bp upstream.
Plasmid pRB4929 was used to construct the recombinant virus R7537.
Plasmid pRB103, containing the BamHI Q fragment, was used to
repair the deletion in the TK gene of R7537, resulting in the
recombinant virus R7538. pRB4794 has been described elsewhere
(28). It contains the 1,800-bp NcoI fragment of
BamHI S, spanning the region between the start codons of the
0 and
134.5 genes. It was used as a probe for analyses of recombinant viral DNA and was used to repair the mutations in the ORF P domain of R7538 resulting in the recombinant virus R7543.
Construction of recombinant viruses.
Viral stocks and
titrations of viruses were done in Vero cells (American Type Culture
Collection). R7537 was constructed by cotransfection of rabbit skin
cells (originally obtained from J. McClaren) with pRB4929, which
contains the ORF P initiator methionine codon mutation, with R3659
viral DNA (Fig. 1, lane 4) which contains a deletion in the TK gene,
and with an
27 promoter-driven TK gene replacement of the 1,100-bp
StuI-NcoI fragment encoding the ORF P and
134.5 genes. TK
viruses were selected by
plating the progeny of the cotransfection on 143TK
cells
overlaid with Dulbecco modified Eagle medium containing 5% newborn
calf serum and 40 µg of bromodeoxyuridine per ml of medium.
Plaque-purified stocks were prepared as described elsewhere (41). Viral DNA was isolated from infected cells and
purified on a 5 to 20% potassium acetate gradient as described
elsewhere (27). Viral DNAs from single plaques were analyzed
for the presence of novel AvrII endonuclease restriction
sites diagnostic of the initiator methionine codon mutation. The TK
gene of R7537 was repaired by plating the progeny of the cotransfection
of rabbit skin cells with R7537 DNA and pBR103, which contains the
BamHI Q fragment, on 143TK
cells overlaid in
Dulbecco modified Eagle medium containing 5% fetal bovine serum,
hypoxanthine, aminopterin, and thymidine. Virus was isolated, purified,
and analyzed as described above. This process resulted in the isolation
of R7538, which contains a wild-type BamHI Q fragment and
the ORF P initiator methionine codon mutation. The mutations in the ORF
P gene of R7538 were repaired by cotransfection of rabbit skin cells
with R7538 viral DNA and pRB4794, which contains the 1,800-bp
NcoI fragment from BamHI S of HSV-1(F). Plaques
were isolated, and viral DNA was analyzed for a wild-type restriction
endonuclease pattern indicating the absence of the introduced
EcoRI and AvrII sites within BamHI S. R7543 has a wild-type restriction endonuclease pattern and therefore
has a wild-type genotype.
Analyses of viral DNAs. Viral DNAs were digested with appropriate restriction enzymes as detailed in the legend to Fig. 1. They were then subjected to electrophoresis on a 28-cm-long, 0.85% agarose gel and transferred to a Zeta probe (Bio-Rad, Richmond, Calif.) by capillary action in 0.5 M NaOH. The membrane was rinsed in 2× SSC (0.3 M NaCl plus 0.015 M sodium citrate) and prehybridized in 30% formamide-6× SSC-1% milk-1% sodium dodecyl sulfate (SDS)-100 µg of single-stranded calf thymus DNA per ml for 30 min at 68°C. Denatured, 32P-labeled pRB4794 (106 cpm) was then added overnight, and the blot was rinsed as recommended by the manufacturer. Autoradiographic images were obtained on Kodak XAR5 film.
Immunoblots.
Immunoblots were done as previously described
(27). Briefly, infected cells were scraped into
phosphate-buffered saline (PBS), pelleted under low-speed
centrifugation, resuspended in disruption buffer containing 0.7 M
-mercaptoethanol, 2% SDS, 50 mM Tris, and 2.75% sucrose, sonicated
briefly, boiled, and electrophoretically separated on a denaturing
polyacrylamide gel cross-linked with
N,N'-diallyltartardiamide (Bio-Rad). The
electrophoretically separated, denatured proteins were electrically
transferred to a nitrocellulose sheet, blocked, reacted with the
appropriate antiserum, rinsed, and reacted with either goat anti-rabbit
immunoglobulin G (IgG) conjugated to alkaline phosphatase for rabbit
polyclonal antisera or goat anti-mouse IgG conjugated to alkaline
phosphatase for mouse monoclonal antisera. Proteins were then rinsed
again and developed as recommended by the manufacturer (Bio-Rad).
Viral replication in cell culture.
Triplicate
25-cm2 plaque dishes containing Vero or SK-N-SH cells were
infected with 5 PFU of HSV-1(F), R7538(P
/O
), or R7543(P
/O
)R. Cells were harvested at 6, 12, or 24 h, washed in PBS, resuspended in 1 ml of sterile milk, taken through three freeze-thaw cycles, sonicated, and used to infect Vero cells in 25-cm2 plaque
dishes at 10-fold dilutions. Cells were maintained in 199"O"
medium, and plaques were counted 2 days after infection.
Intracranial inoculation of mice. CBA/J mice (3.5 weeks old) from Jackson Laboratory were anesthetized with pentobarbital sodium (Nembutal) and injected intracerebrally with 10-fold serial dilutions of virus, seven mice per dilution. Mice were monitored daily; mortality from 2 to 21 days after infection was attributed to the inoculated virus. The 50% lethal dose (LD50) ratios were calculated by the method of Reed and Muench (44).
Assays of viral replication in murine eye and trigeminal ganglia. CBA/J mice from Jackson Laboratory, 4.5 weeks of age, were anesthetized and inoculated with 10 µl (5 × 105 PFU) of virus on scarified corneas as previously described (29). Mice were sacrificed 1, 3, 5, and 7 days after infection; the eyes or trigeminal ganglia were removed, placed in 1 ml of 199V containing nystatin, homogenized in a mechanical tissue grinder, and plated on Vero cells (6 eyes or 20 ganglia per virus for each time point). Plaques were counted 2 days after being seeded on Vero cells.
Viral reactivation in murine trigeminal ganglia. CBA/J mice from Jackson Laboratory, 4.5 weeks of age, were anesthetized and inoculated with 10 µl of virus on scarified corneas as described above. Mice were sacrificed at 30 days after infection, and the trigeminal ganglia were removed, placed in 1 ml of 199V containing nystatin, and incubated for 5 days. The ganglia were then homogenized in a mechanical tissue grinder and plated on Vero cells (28 ganglia per virus). Cytopathic effect (CPE) was monitored daily for 8 days after cocultivation.
Quantitation of latent virus.
CBA/J mice (4.5 weeks old)
were ocularly infected as described above. At 30 days after infection,
26 trigeminal ganglia per virus were removed, flash frozen, and stored
at
80°C. Quantitative PCR was performed as previously described
(23, 24). Briefly, ganglia were homogenized in 1 ml of
solubilization solution (5 M guanidine thiocyanate, 50 mM Tris [pH
7.5], 10 mM EDTA, 5%
-mercaptoethanol) using a Dounce homogenizer
mechanical tissue grinder. DNA was precipitated, resuspended in PCR
buffer, and digested with 0.2 µg of proteinase K/ml at 55°C for
2 h, 80°C for 20 min, and 95°C for 5 min. One hundred
nanograms of DNA was used for PCR with the following primers specific
for the viral TK gene or the cellular
-actin gene: TK-1,
5'-CTTAACAGCGTCAACAGCGTGCCG; TK-2,
5'-CAAAGAGGTGCGGGAGT; Act-1,
5'-AACCCTAAGGCCAACCGTGAAAAGATGACC; Act-2,
5'-CCAGGGAGGAAGAGGATGCGGC. PCR was performed under
previously described conditions (24). TK products were
amplified for 30 cycles at 95°C for 1 min, 55°C for 1 min, and
72°C for 2 min, with a final extension of 5 min at 72°C. Actin PCR
conditions were as above except that the annealing temperature was
60°C. Aliquots of the PCR mixture were separated by nondenaturing
polyacrylamide gel electrophoresis, electroblotted to a Zeta probe
nylon membrane, denatured, and probed with the following
32P-labeled oligonucleotides internal to the PCR primers:
TK-3, 5'-CAGATCTTGGTGGCGTG; Act-3,
5'-GCTCTAGACTTCGAGCAGGAGATGGCCACT. The labeled probes were
hybridized overnight at 50°C in 5× SSC-7% SDS-1× Denhardt's
solution-25 mM sodium phosphate, pH 7.2, and washed as recommended by
the manufacturer. The levels of amplified TK product were quantitated
with a Storm phosphorimager and compared with a linear standard curve
generated by PCR of 100 ng of uninfected murine trigeminal ganglion DNA
spiked with 10-fold dilutions of purified HSV-1(F) DNA. The values were
normalized for DNA content by comparison of the amplified
-actin product.
| |
RESULTS |
|---|
|
|
|---|
Construction and characterization of the recombinant virus
R7538(P
/O
), containing a mutated ORF P initiator methionine codon,
and the repaired recombinant virus, R7543(P
/O
)R.
The
procedures for the construction of recombinant viruses R7538(P
/O
)
and R7543(P
/O
)R are described in Materials and Methods. R7538(P
/O
) contains two nucleotide substitutions, one at the initiator methionine codon (ATG
ATA) and one 15 bp upstream creating a unique AvrII restriction endonuclease site
(CCCAGG
CCTAGG). The mutation creating the novel
AvrII restriction endonuclease site also introduced a TAG
stop codon into the predicted ORF O gene, upstream of the ORF P
initiator methionine codon. Both mutations are in wobble codons of
134.5, and as such they do not alter the amino acid
sequence of the
134.5 protein. The genotype of R7538(P
/O
) was verified by the presence of the unique
AvrII restriction endonuclease site diagnostic of the ORF P
initiator methionine codon mutation, the location of which is shown in
Fig. 1, line 6. R7538(P
/O
) DNA was purified and incubated with
restriction endonucleases NcoI and AvrII,
electrophoretically separated on 0.85% agarose gels, transferred to
Zeta probe membranes, and hybridized with 32P-labeled
pRB4794, which contains the 1,800-bp NcoI fragment of BamHI S (Fig. 2, lane 3).
Restriction endonuclease cleavage of R7538(P
/O
) with
NcoI and AvrII resulted in the predicted 1,070- and 730-bp DNA fragments (Fig. 1, line 7, and Fig. 2, bands C and D),
verifying the presence of the ORF P initiator methionine codon
mutation. This pattern is distinct from those of the 1,800-bp fragment
of HSV-1(F) (Fig. 1, line 3, and Fig. 2, band A) and the 700-bp DNA
fragment of the parental virus R3659 (Fig. 1, line 5, and Fig. 2, band
B).
|
/O
) and pRB4794 (described above).
Viral DNAs from plaque isolates of progeny virus were screened for the
wild-type restriction pattern. Incubation of R7543(P
/O
)R with
NcoI and AvrII resulted in the wild-type 1,800-bp band (Fig. 1, line 9, and Fig. 2, band E), indicating that the introduced mutations were replaced with wild-type sequences.
Expression of ORF O and
134.5 proteins in cells
infected with HSV-1(F), R7538(P
/O
), and R7543(P
/O
)R recombinant
viruses.
The ORF P initiator methionine codon mutation previously
was shown to prevent ORF P translation from a derepressed ORF P
transcript (42). The effect of the mutations on ORF O
expression was unknown. Therefore, cells in replicate
25-cm2 flasks were mock infected or infected (10 PFU/cell)
with HSV-1(F), R7538(P
/O
), or R7543(P
/O
)R at 4°C and
maintained at 39.5°C, the nonpermissive temperature for ICP4. After
20 h the cells were harvested, lysed by sonication in disruption
buffer, boiled for 5 min, subjected to electrophoresis in denaturing
polyacrylamide gels, transferred to a nitrocellulose sheet, and reacted
with polyclonal antiserum specific for ORF O. As shown in Fig.
3A, ORF O accumulated in cells infected
with either HSV-1(F) or the repair virus R7543(P
/O
)R and maintained
at the nonpermissive temperature for ICP4. ORF O was not detected in
R7538(P
/O
), indicating that the introduced mutations are sufficient
to prevent ORF O expression.
|
134.5 gene, we verified that
134.5
expression in the recombinant viruses was comparable to that in the
wild-type virus. Cells in replicate 25-cm2 flasks were mock
infected or infected with 10 PFU of HSV-1(F), R7538(P
/O
), and
R7543(P
/O
)R and maintained at 37°C. Infected-cell lysates were
processed as described above and reacted with polyclonal antiserum BR4,
specific for
134.5. As shown in Fig. 3B, the
134.5 protein was present in all infected lysates at
comparable levels. The results of Fig. 3 show that, in addition to
precluding ORF P protein translation, the mutations introduced into
R7538(P
/O
) prevent ORF O synthesis without affecting the expression
of the antisense
134.5 gene.
Replication of wild-type and mutant viruses in cell culture and in
vivo.
The replication competence of recombinant viruses was tested
in four series of experiments involving (i) the production of infectious progeny in cell culture, (ii) determination of the neurovirulence of the recombinant viruses compared to that of the wild
type, (iii) the isolation of infectious virus from murine eyes, and
(iv) the isolation of infectious virus from murine trigeminal ganglia.
In the first series of experiments, replicate 25-cm2
cultures of Vero or SK-N-SH cells were infected with 5 PFU of HSV-1(F)
or R7538(P
/O
) per cell. Infected cells were harvested at 6, 12, and
24 h after infection. As shown in Table
1, the yields of HSV-1(F) and
R7538(P
/O
) viruses were comparable in Vero cells and in SK-N-SH
cells. Thus, the absence of ORF O and ORF P protein synthesis did not
affect viral growth in cells of neuronal and nonneuronal origin.
|
/O
), and R7543(P
/O
)R was tested. Neurovirulence represents the capacity of HSV to replicate in and destroy the central
nervous system and, as such, is frequently used to assess the
replication competence of recombinant viruses in vivo. Four-week-old CBA/J mice were inoculated intracranially with 10-fold dilutions of
HSV-1(F), R7538(P
/O
), or R7543(P
/O
)R, seven mice per dilution, as described in Materials and Methods. Mice were monitored daily, and
mortality was recorded from days 2 to 21 after infection. The
PFU/LD50 ratios for all viruses tested were within a
2.5-fold range. HSV-1(F) and R7543(P
/O
) had PFU/LD50
ratios of 63 and 60, respectively, while the value for R7538(P
/O
)
was 164. Thus, the absence of ORF O and ORF P protein synthesis in
cells infected with R7538(P
/O
) did not significantly affect the
ability of the virus to replicate in cell culture or the murine central
nervous system.
In the third series of experiments, 4.5-week-old CBA/J mice were
infected with 5 × 105 PFU of HSV-1(F),
R7538(P
/O
), or R7543(P
/O
)R per eye. At days 1, 3, 5, and 7 after infection, three mice per group were anesthetized and sacrificed
and the eyes were removed, washed, homogenized in 1 ml of 199V with
nystatin using a mechanical tissue grinder, and frozen. Vero cells in
replicate 25-cm2 flasks were infected with 10-fold
dilutions of the respective virus, maintained in the presence of HSV-1
neutralizing antibody, and plaque titers were determined 2 days after
infection. As shown in Table 2, the
amounts of infectious R7538(P
/O
), HSV-1(F), and R7543(P
/O
)R
isolated from eyes following ocular infection generally fell within a
threefold range. The amounts of infectious R7538(P
/O
) were not
statistically different from those of HSV-1(F) or R7543(P
/O
)R at
any of the times tested (P > 0.05). Thus, the relative
amounts of infectious wild-type and recombinant viruses isolated from
the site of inoculation were indistinguishable.
|
/O
), or R7543(P
/O
)R per eye. At days 3 and 5 after
infection, the trigeminal ganglia were removed and virus was titered as
described above. As shown in Table 3, the amounts of infectious R7538(P
/O
), HSV-1(F), and R7543(P
/O
)R isolated from ganglia 3 days after ocular infection fell within a
threefold range (9.0 × 103, 2.7 × 104, and 2.9 × 104 PFU per ganglion,
respectively). At day 5, the level of infectious R7538(P
/O
) was 2 to 3 log units less than that of HSV-1(F) or the repair virus (3.2 × 102, 1.4 × 105, and 7.7 × 104 PFU per ganglion, respectively). It is unclear whether
the decrease in infectious R7538(P
/O
) virus at day 5 reflects an
alteration in the efficiency of the establishment of latency. We
conclude that at day 3, a time at which acute infection and the
establishment of latency. We conclude that at day 3, a time at which
acute infection and the establishment of latency are occurring in mice,
infectious R7538(P
/O
) was present in trigeminal ganglia at levels
comparable to those of HSV-1(F) and the repair virus.
|
Reactivation from latency in mice infected with HSV-1(F),
R7538(P
/O
), and R7543(P
/O
)R.
The significance of ORF O and
ORF P in the latent life cycle was assessed by measuring the
reactivation of wild-type and recombinant viruses. CBA/J mice (4.5 weeks old) were infected by ocular scarification with 5 × 105 PFU of HSV-1(F), R7538(P
/O
), or R7543(P
/O
)R per
eye. After 30 days, a time at which replicating HSV-1 or R7538(P
/O
)
could not be isolated in this animal model (reviewed in reference
15) (data not shown), mice were anesthetized; the
trigeminal ganglia were removed, incubated for 5 days in 199V plus
nystatin, homogenized, and cocultivated in replicate 25-cm2
flasks containing Vero cells; and CPE was scored for each ganglion. Figure 4 shows the percentage of ganglia
that produced reactivated virus versus the day after cocultivation.
Both HSV-1(F)- and R7543(P
/O
)R-infected ganglia reactivated virus
in 100% of the samples, with 90% showing obvious CPE 1 day after
cocultivation. R7538(P
/O
)-infected ganglia reactivated virus in
95% of samples; however, CPE in 90% of the ganglia was not achieved
until 3 days after cocultivation. This likely reflects smaller amounts
of reactivated virus. The data indicate that ORF O and ORF P proteins
are not required for reactivation from latency, but a virus precluded
from synthesizing ORF O and ORF P proteins reactivated with reduced
kinetics.
|
-actin gene
(24). Aliquots of the PCR mixture were separated by
nondenaturing polyacrylamide gel electrophoresis, electroblotted to a
nylon membrane, denatured, and probed with 32P-labeled
oligonucleotides internal to the PCR primers. The levels of amplified
TK gene product were quantified with a Storm phosphorimager and
compared with a linear standard curve generated by PCR of 100 ng of
uninfected murine trigeminal ganglion DNA spiked with 10-fold dilutions
of purified HSV-1(F) DNA. No amplified TK gene product was detected in
uninfected murine trigeminal ganglia samples (data not shown). The
values were normalized for DNA content by comparison of the amplified
-actin gene product. The results of these studies are shown in Table
4. Ganglia latently infected with
R7538(P
/O
) contained 0.14 +/
0.03 viral DNA copies per cell
equivalent, whereas the HSV-1(F) latent DNA copy number was estimated
to be sixfold higher, 0.84 copies per cell (P < 0.005). The amount of latent R7543(P
/O
)R was eightfold higher
than the amount of R7538(P
/O
), 1.10 copies per cell (P < 0.0001). These results indicate that ORF O and ORF P proteins
may play a role in the ultimate number of viral DNA copies maintained
in the latent state.
|
| |
DISCUSSION |
|---|
|
|
|---|
A unique property of HSV is that it carries a large number of accessory genes designed in large part to control both the intracellular and extracellular environment in which it replicates. Latency is a significant mechanism for the perpetuation of HSV in human populations. Other herpesviruses, notably Epstein-Barr virus and other members of the gammaherpesvirus subfamily, have evolved elaborate mechanisms for the establishment of the latent state by virally encoded proteins. The presumption that HSV would also encode functions designed to facilitate the establishment of latency was the basis of the search that led to the identification of ORFs P and O.
ORF P and O and their products appear to be ideal candidates for the
control of the latent state. Specifically, (i) ORF O and ORF P are
located in the domain transcribed during latency, (ii) both ORFs are
completely repressed during productive infection by ICP4, the major
viral transcriptional transactivator/repressor, (iii) the ORF P protein
inhibits the synthesis of the important
-regulatory proteins ICP0
and ICP22 in cells infected with ORF P-derepressed viruses, and (iv)
the ORF O protein made under similar circumstances binds to and
inhibits ICP4 binding to its cognate DNA site in vitro. The objective
of the studies described in this report was to test the role of ORF O
and ORF P in the establishment of latency in the mouse model in vivo.
To test the role of ORF O and ORF P proteins, we constructed the
recombinant virus R7538(P
/O
), in which the initiator methionine codon of both coding sequences was mutated such that it would not
affect the amino acid sequence of the product of the antisense
134.5 gene. This virus contained two nucleotide
substitutions, one mutating the ORF P initiator methionine codon and
the other creating a unique restriction endonuclease site 15 bp
upstream. These mutations were repaired in the recombinant virus
R7543(P
/O
)R. The salient features of the results and the key
conclusions derived from characterization of the recombinant viruses follow.
(i) The initiator methionine codon mutation was previously shown to
preclude ORF P protein expression in the context of a virus with ORF P
transcription derepressed (42). Characterization of
R7538(P
/O
) showed that this mutation also prevents ORF O protein
expression in cells infected and maintained at 39.5°C, the
nonpermissive temperature for ICP4. The absence of ORF P and ORF O
proteins is not surprising since earlier studies have shown that ORF O
and ORF P proteins share the ORF P protein initiator methionine and
then diverge within the first 34 amino acids of the ORF P protein
(43). To preclude a potential low level of expression of ORF
O from the single methionine codon in its own reading frame, the base
substitution creating a unique restriction endonuclease site also
introduced a TAG stop codon in the predicted ORF O frame upstream of
the ORF P initiator methionine codon.
134.5 protein
expression and function in the mutant virus, as assayed by replication
in neuronal cell lines and determination of neurovirulence, were the
same as those in the wild type.
(ii) Consistent with their absence in productively infected cells, ORF
O and ORF P proteins play no discernible role in viral replication in
cell culture and in vivo. Specifically, R7538(P
/O
) replicated to
wild-type levels in cell lines of neuronal and nonneuronal origin
(SK-N-SH and Vero cells, respectively). Neurovirulence was similarly
unaffected. HSV-1(F), R7538(P
/O
), and R7543(P
/O
)R all had
PFU/LD50 ratios within a 2.5-fold range. Replication at a
peripheral site was tested by the isolation of infectious virus from
eyes following ocular infection. Differences in the amounts of
infectious HSV-1(F), R7538(P
/O
), and R7543(P
/O
)R were not statistically significant at 1, 3, 5, and 7 days after infection. A
fourth assay of replication competence was the recovery of infectious virus from ganglia at the peak of acute infection. After 3 days, the
amounts of infectious wild-type and recombinant viruses fell within a
threefold range. Thus at a time in which replication and the
establishment of latency are occurring concurrently, similar levels of
wild-type and recombinant viruses were present in the trigeminal
ganglion. Interestingly, at 5 days after ocular infection, the level of
infectious R7538(P
/O
) dropped 2 to 3 log units compared with the
level of wild-type or repair virus. The mechanism responsible for this
decrease is uncertain, but the observation itself does not support the
hypothesis that ORF O and P proteins play a significant role in the
establishment of latency.
(iii) R7538(P
/O
) virus appears to establish latent infections at
reduced levels compared with those of the wild-type parent and repaired
viruses. HSV-1(F) and R7543(P
/O
)R reactivated in 100% of infected
ganglia with rapid kinetics. The virus with ORF O and ORF P mutated
reactivated in 95% of infected ganglia; however, reactivation occurred
with reduced kinetics. The decrease in the amount of virus recovered
after explanation of trigeminal ganglia correlated with the six- to
eightfold-lower numbers of copies of viral DNA/cell in trigeminal
ganglia harboring latent R7538(P
/O
) than in those harboring
wild-type or repaired viruses.
The results presented here suggest that ORF O and ORF P proteins may
play a role but are not essential for the establishment of latency in
the mouse model. One interpretation of our results is that the
establishment of latency is a multifactorial event involving several
gene products both inside and outside of the HSV LAT domain and that
each of them contributes to the switching off of replicative functions
in dorsal root neurons. An alternative hypothesis is that ORF P and ORF
O are effective in the maintenance phase rather than the establishment
phase of latency. For example, it is conceivable that the reduction in
the DNA copy number reflects a loss of neurons harboring virus due to
reactivation of the latent virus and consequent destruction of neurons
harboring them rather than a reduction in the number of neurons in
which latent infections had been established. Sorting out this role of
ORF P and O would require construction of viral mutants constitutively
expressing ORF P and ORF O proteins. This is not an easy task since the
expression of ORFs P and O and of the
134.5 gene is
mutually exclusive. The
134.5 gene plays a key role in
breaching host defenses against infection; failure to express ICP34.5
would significantly impair productive infection and the ability of the
virus to establish latent infections. The solution to this problem
remains to be found.
| |
ACKNOWLEDGMENTS |
|---|
We thank Lindsay Smith for expert technical assistance.
These studies were aided by grants from the National Cancer Institute (CA47451, CA71933, and CA78766) and the United States Public Health Service.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: The Marjorie B. Kovler Viral Oncology Laboratories, The University of Chicago, 910 E. 58th St., Chicago, IL 60637. Phone: (773) 702-1898. Fax: (773) 702-1631. E-mail: bernard{at}cummings.uchicago.edu.
Present address: Department of Microbiology and Immunology,
University of California, San Francisco, CA 94143.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ackermann, M.,
J. Chou,
M. Sarmiento,
R. A. Lerner, and B. Roizman.
1986.
Identification by antibody to a synthetic peptide of a protein specified by a diploid gene located in the terminal repeats of the L component of herpes simplex virus genome.
J. Virol.
58:843-850 |
| 2. | Block, T. M., S. Deshmane, J. Masonis, J. Maggioncalda, T. Valyi-Nagi, and N. W. Fraser. 1993. An HSV LAT null mutant reactivates slowly from latent infection and makes small plaques on CV-1 monolayers. Virology 192:618-630[CrossRef][Medline]. |
| 3. | Bloom, D. C., G. Devi-Rao, E. K. Wagner, L. T. Feldman, and J. G. Stevens. 1996. A 348-base-pair region in the latency-associated transcript facilitates herpes simplex virus 1 reactivation. J. Virol. 70:2449-2459[Abstract]. |
| 4. |
Bohenzky, R. A.,
A. G. Papavassiliou,
I. H. Gelman, and S. Silverstein.
1993.
Identification of a promoter mapping within the reiterated sequences that flank the herpes simplex virus type 1 UL region.
J. Virol.
67:632-642 |
| 5. |
Bruni, R., and B. Roizman.
1996.
Open reading frame P a herpes simplex virus gene repressed during productive infection encodes a protein that binds a splicing factor and reduces synthesis of viral proteins made from spliced mRNA.
Proc. Natl. Acad. Sci. USA
93:10423-10427 |
| 6. | Chen, S. H., M. F. Kramer, P. A. Schaffer, and D. M. Coen. 1997. A viral function represses accumulation of transcripts from productive-cycle genes in mouse ganglia latently infected with herpes simplex virus. J. Virol. 71:5578-5584. |
| 7. |
Chou, J., and B. Roizman.
1986.
The terminal a sequence of herpes simplex virus genome contains the promoter of a gene located in the repeat sequences of the L component.
J. Virol.
57:629-637 |
| 8. |
Chou, J., and B. Roizman.
1992.
The 134.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells.
Proc. Natl. Acad. Sci. USA
89:3266-3270 |
| 9. |
Chou, J.,
E. R. Kern,
R. J. Whitley, and B. Roizman.
1990.
Mapping of herpes simplex virus-1 neurovirulence to 134.5, a gene nonessential for growth in culture.
Science
250:1262-1266 |
| 10. |
Devi-Rao, G. B.,
S. A. Goodart,
L. M. Hecht,
R. Rochford,
M. K. Rice, and E. K. Wagner.
1991.
Relationship between polyadenylated and nonpolyadenylated herpes simplex virus type 1 latency-associated transcripts.
J. Virol.
65:2179-2190 |
| 11. |
Dixon, R. A. F., and P. A. Schaffer.
1980.
Fine-structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175.
J. Virol.
36:189-203 |
| 12. |
Ejercito, P. M.,
E. D. Kieff, and B. Roizman.
1967.
Characterization of herpes simplex virus strains differing in their effects on social behavior of infected cells.
J. Gen. Virol.
2:357-364 |
| 13. |
Faber, S. W., and K. W. Wilcox.
1986.
Association of the herpes simplex virus regulatory protein ICP4 with specific nucleotide sequences in DNA.
Nucleic Acids Res.
14:6067-6083 |
| 14. |
Farrell, M. J.,
A. T. Dobson, and L. T. Feldman.
1991.
Herpes simplex virus latency-associated transcript is a stable intron.
Proc. Natl. Acad. Sci. USA
88:790-794 |
| 15. | Fawl, R. L., and B. Roizman. 1994. The molecular basis of herpes simplex virus pathogenicity. Semin. Virol. 5:261-271[CrossRef]. |
| 16. | Garber, D. A., P. A. Schaffer, and D. M. Knipe. 1997. A LAT-associated function reduces productive-cycle gene expression during acute infection of murine sensory neurons with herpes simplex virus type 1. J. Virol. 71:5885-5893[Abstract]. |
| 17. |
He, B.,
M. Gross, and B. Roizman.
1997.
The 134.5 protein of herpes simplex virus I complexes with protein phosphatase 1 to dephosphorylate the subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase.
Proc. Natl. Acad. Sci. USA
94:843-848 |
| 18. | Hill, J. M., F. Sedarati, R. T. Javier, E. K. Wagner, and J. G. Stevens. 1990. Herpes simplex virus latent phase transcription facilitates in vivo reactivation. Virology 174:117-125[CrossRef][Medline]. |
| 19. |
Hill, J. M.,
J. B. Maggioncalda,
H. H. Garza,
Y. H. Su,
N. W. Fraser, and T. M. Block.
1996.
In vivo epinephrine reactivation of ocular herpes simplex virus type 1 in the rabbit is correlated to a 370-base-pair region located between the promoter and the 5' end of the 2.0-kilobase latency-associated transcript.
J. Virol.
70:7270-7274 |
| 20. |
Honess, R. W., and B. Roizman.
1974.
Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins.
J. Virol.
14:8-19 |
| 21. |
Honess, R. W., and B. Roizman.
1975.
Regulation of herpesvirus macromolecular synthesis: sequential transition of polypeptide synthesis requires functional viral polypeptides.
Proc. Natl. Acad. Sci. USA
72:1276-1280 |
| 22. | Javier, R. T., J. G. Stevens, V. B. Dissette, and E. K. Wagner. 1988. A herpes simplex virus transcript abundant in latently infected neurons is dispensable for establishment of the latent state. Virology 166:254-257[CrossRef][Medline]. |
| 23. |
Katz, J. P.,
E. T. Bodin, and D. M. Coen.
1990.
Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia infected with replication-incompetent mutants.
J. Virol.
64:4288-4295 |
| 24. | Kramer, M. F., and D. M. Coen. 1995. Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus. J. Virol. 69:1389-1399[Abstract]. |
| 25. |
Krause, P. R.,
K. D. Croen,
S. E. Straus, and J. M. Ostrove.
1988.
Detection and preliminary characterization of herpes simplex virus type 1 transcripts in latently infected human trigeminal ganglia.
J. Virol.
62:4819-4823 |
| 26. |
Kristie, T., and B. Roizman.
1986.
4, the major regulatory protein of herpes simplex type 1, is stably and specifically associated with promoter-regulatory domains of genes and of selected other viral genes.
Proc. Natl. Acad. Sci. USA
83:3218-3222 |
| 27. |
Lagunoff, M., and B. Roizman.
1994.
Expression of a herpes simplex virus 1 open reading frame antisense to the 134.5 gene and transcribed by an RNA 3' coterminal with the unspliced latency-associated transcript.
J. Virol.
68:6021-6028 |
| 28. | Lagunoff, M., and B. Roizman. 1995. The regulation of synthesis and properties of the protein product of open reading frame P of the herpes simplex virus 1 genome. J. Virol. 69:3615-3623[Abstract]. |
| 29. | Lagunoff, M., G. Randall, and B. Roizman. 1996. Phenotypic properties of herpes simplex virus 1 containing a derepressed open reading frame P gene. J. Virol. 70:1810-1817[Abstract]. |
| 30. |
Lee, L. Y., and P. A. Schaffer.
1998.
A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of 134.5 transcripts and latency-associated transcripts.
J. Virol.
72:4250-4264 |
| 31. |
Leib, D. A.,
C. L. Bogard,
M. Kosz-Vnenchak,
K. A. Hicks,
D. M. Coen,
D. M. Knipe, and P. A. Schaffer.
1989.
A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency.
J. Virol.
63:2893-2900 |
| 32. |
Leib, D. A.,
D. M. Coen,
C. L. Bogard,
K. A. Hicks,
O. R. Yager,
D. M. Knipe,
K. L. Tyler, and P. A. Schaffer.
1989.
Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency.
J. Virol.
63:759-768 |
| 33. |
Leopardi, R.,
N. Michael, and B. Roizman.
1995.
Repression of the herpes simplex virus 1 4 gene by its gene product (ICP4) within the context of the viral genome is conditioned by the distance and stereoaxial alignment of the ICP4 DNA binding site relative to the TATA box.
J. Virol.
69:3042-3048[Abstract].
|
| 34. |
Michael, N., and B. Roizman.
1993.
Repression of the herpes simplex virus 1 a4 gene by its gene product occurs within the context of the viral genome and is associated with all three identified cognate sites.
Proc. Natl. Acad. Sci. USA
90:2286-2290 |
| 35. |
Michael, N.,
D. Spector,
P. Mavromara-Nazos,
T. M. Kristie, and B. Roizman.
1988.
The DNA-binding properties of the major regulatory protein 4 of herpes simplex viruses.
Science
239:1531-1534 |
| 36. |
Mitchell, W. J.,
R. P. Lirette, and N. W. Fraser.
1990.
Mapping of low abundance latency-associated RNA in the trigeminal ganglia a mice latently infected with herpes simplex virus type 1.
J. Gen. Virol.
71:125-132 |
| 37. | Perng, G. C., R. L. Thompson, N. M. Sawtell, W. E. Taylor, S. M. Slanina, H. Ghiasi, R. Kaiwar, A. B. Nesburn, and S. L. Wechsler. 1995. An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation. J. Virol. 69:3033-3041[Abstract]. |
| 38. | Perng, G. C., H. Ghiasi, S. M. Slanina, A. B. Nesburn, and S. L. Wechsler. 1996. High-dose ocular infection with a herpes simplex virus type 1 ICP34.5 deletion mutant produces no corneal disease or neurovirulence yet results in wild-type levels of spontaneous reactivation. J. Virol. 70:2883-2893[Abstract]. |
| 39. |
Perng, G. C.,
C. Jones,
J. Ciacci-Zanella,
M. Stone,
G. Henderson,
A. Yukht,
S. M. Slanina,
F. M. Hofman,
H. Ghiasi,
A. B. Nesburn, and S. L. Wechsler.
2000.
Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript.
Science
287:1500-1503 |
| 40. |
Post, L. E.,
S. Mackem, and B. Roizman.
1981.
Regulation of genes of herpes simplex virus: expression of chimeric genes produced by fusion of thymidine kinase with gene promoters.
Cell
24:555-565[CrossRef][Medline].
|
| 41. |
Post, L. E., and B. Roizman.
1981.
A generalized technique for deletion of specific genes in large genomes: gene 22 of herpes simplex virus 1 is not essential for growth.
Cell
25:227-232[CrossRef][Medline].
|
| 42. |
Randall, G., and B. Roizman.
1997.
Transcription of the derepressed open reading frame P of herpes simplex virus 1 precludes the expression of the antisense 134.5 gene and may account for attenuation of the mutant virus.
J. Virol.
71:7750-7757[Abstract].
|
| 43. |
Randall, G.,
M. Lagunoff, and B. Roizman.
1997.
The product of ORF O located within the domain of herpes simplex virus 1 genome transcribed during latent infection binds to and inhibits in vitro binding of infected cell protein 4 to its cognate DNA site.
Proc. Natl. Acad. Sci. USA
94:10379-10384 |
| 44. | Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497. |
| 45. |
Resnick, J.,
B. A. Boyd, and M. L. Haffey.
1989.
DNA binding by the herpes simplex virus type 1 ICP4 protein is necessary for efficient down regulation of the ICP0 promoter.
J. Virol.
63:2497-2503 |
| 46. | Rivera-Gonzalez, R., A. N. Imbalzano, G. Gu, and N. A. Deluca. 1994. The role of ICP4 repressor activity in temporal expression of the IE-3 and latency-associated transcript promoters during HSV-1 infection. Virology 202:550-564[CrossRef][Medline]. |
| 47. |
Rock, D. L.,
A. B. Nesburn,
H. Ghiasi,
J. Ong,
T. L. Lewis,
J. R. Lokensgard, and S. L. Wechsler.
1987.
Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1.
J. Virol.
61:3820-3826 |
| 48. | Rodahl, E., and L. Haarr. 1997. Analysis of the 2-kilobase latency-associated transcript expressed in PC12 cells productively infected with herpes simplex virus type 1: evidence for a stable, nonlinear structure. J. Virol. 71:1703-1707[Abstract]. |
| 49. |
Roizman, B.
1996.
The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors.
Proc. Natl. Acad. Sci. USA
93:11307-11312 |
| 50. | Roizman, B., and A. E. Sears. 1996. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed, p. 2231-2295. Lippincott-Raven Publishers, Philadelphia, Pa. |
| 51. |
Sedarati, F.,
K. M. Izumi,
E. K. Wagner, and J. G. Stevens.
1989.
Herpes simplex virus type 1 latency-associated transcription plays no role in establishment or maintenance of a latent infection in murine sensory neurons.
J. Virol.
63:4455-4458 |
| 52. |
Spivack, J. G., and N. W. Fraser.
1987.
Detection of herpes simplex virus type 1 transcripts during latent infection in mice.
J. Virol.
61:3841-3847 |
| 53. |
Spivack, J. G.,
M. U. Fareed,
T. Valyi-Nagy,
T. C. Nash,
J. S. O'Keefe,
R. M. Gesser,
E. A. McKie,
A. R. Maclean,
N. W. Fraser, and S. M. Brown.
1995.
Replication, establishment of latent infection, expression of the latency-associated transcripts and explant reactivation of herpes simplex virus type 1 gamma 34.5 mutants in a mouse eye model.
J. Gen. Virol.
76:321-332 |
| 54. | Steiner, I., J. G. Spivack, R. P. Lirette, S. M. Brown, A. R. MacLean, J. H. Subak-Sharpe, and N. W. Fraser. 1989. Herpes simplex virus type 1 latency-associated transcripts are evidently not essential for latent infection. EMBO J. 8:505-511[Medline]. |
| 55. |
Stevens, J. G.,
E. K. Wagner,
G. B. Devi-Rao,
M. L. Cook, and L. T. Feldman.
1987.
RNA complementary to a herpesvirus gene mRNA is prominent in latently infected neurons.
Science
235:1056-1059 |
| 56. | Thompson, R. L., and N. M. Sawtell. 1997. The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency. J. Virol. 71:5432-5440[Abstract]. |
| 57. |
Wagner, E. K.,
G. Devi-Rao,
L. T. Feldman,
A. T. Dobson,
Y. Zhang,
W. M. Flanagan, and J. G. Stevens.
1988.
Physical characterization of the herpes simplex virus latency-associated transcript in neurons.
J. Virol.
62:1194-1202 |
| 58. |
Wagner, E. K.,
W. M. Flanagan,
G. Devi-Rao,
Y. Zhang,
J. M. Hill,
K. P. Anderson, and J. G. Stevens.
1988.
The herpes simplex virus latency-associated transcript is spliced during the latent phase of infection.
J. Virol.
62:4577-4585 |
| 59. |
Whitley, R. J.,
E. R. Kern,
S. Chatterjee,
J. Chou, and B. Roizman.
1993.
Replication, establishment of latency, and induced reactivation of herpes simplex virus 134.5 deletion mutants in rodent models.
J. Clin. Investig.
91:2837-2843.
|
| 60. | Wu, T. T., Y. H. Su, T. M. Block, and J. M. Taylor. 1996. Evidence that the latency-associated transcripts of herpes simplex virus type 1 are nonlinear. J. Virol. 70:5962-5967[Abstract]. |
| 61. |
Yeh, L., and P. A. Schaffer.
1993.
A novel class of transcripts expressed with late kinetics in the absence of ICP4 spans the junction between the long and short segments of the herpes simplex virus type 1 genome.
J. Virol.
67:7373-7382 |
| 62. | Zabolotny, J. M., C. Krummenacher, and N. W. Fraser. 1997. The herpes simplex virus type 1 2.0-kilobase latency-associated transcript is a stable intron which branches at a guanosine. J. Virol. 71:4199-4208[Abstract]. |
| 63. |
Zwaagstra, J. C.,
H. Ghiasi,
S. M. Slanina,
A. B. Nesburn,
S. C. Wheatley,
K. Lillycrop,
J. Wood,
D. S. Latchman,
K. Patel, and S. L. Wechsler.
1990.
Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript.
J. Virol.
64:5019-5028 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»